Compare ACCO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCO | MYGN |
|---|---|---|
| Founded | 1893 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.3M | 372.1M |
| IPO Year | 2005 | 1996 |
| Metric | ACCO | MYGN |
|---|---|---|
| Price | $4.50 | $6.06 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | ★ $8.00 | $4.49 |
| AVG Volume (30 Days) | 536.1K | ★ 2.8M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 6.57% | N/A |
| EPS Growth | ★ 141.51 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $1,524,700,000.00 | $771,400,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $1.71 | $5.61 |
| P/E Ratio | $13.10 | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $2.81 | $2.74 |
| 52 Week High | $4.74 | $8.38 |
| Indicator | ACCO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 75.34 |
| Support Level | $4.15 | $5.57 |
| Resistance Level | $4.60 | $6.34 |
| Average True Range (ATR) | 0.12 | 0.30 |
| MACD | 0.00 | 0.17 |
| Stochastic Oscillator | 40.74 | 96.35 |
ACCO Brands Corp is a consumer, technology and business branded products company providing brands and product solutions used in schools, homes and at work. Its brands include At-A-Glance, Barrilito, Buro, Esselte, Five Star, Foroni, GBC, Hilroy, Kensington, Leitz, Mead, PowerA, Quartet, Rapid, Swingline and Tilibra. The Company's product categories include gaming and computer accessories, storage and organization, notebooks, shredding, laminating and binding machines, dry erase boards and do-it-yourself tools. The Company operates through two segments, Americas and International. Americas includes the U.S., Canada, Brazil, Mexico and Chile, and International includes EMEA, Australia, New Zealand and Asia. Its products are sold in the U.S., Europe, Australia, Canada, Brazil and Mexico.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.